
|Videos|July 21, 2020
Dr. Leslie on the Encouraging Evolving Treatment Landscape in MCL
Author(s)Lori A. Leslie, MD
Lori A. Leslie, MD, discusses the encouraging evolving treatment landscape in mantle cell lymphoma.
Advertisement
Lori A. Leslie, MD, lymphoma attending, John Theurer Cancer Center, discusses the encouraging evolving treatment landscape in mantle cell lymphoma (MCL).
It is important to note that past studies in MCL may be outdated as the field is exploding with new information, says Leslie. Prior data painted a more dismal outlook for patients with MCL that may no longer hold true given the current treatment landscape, Leslie adds.
In recent years, many treatment advances have been implemented and will likely contribute to improved patient care in the future, Leslie concludes.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
3
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
4
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
5




































